701-1317

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2014-05-22

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-06-23 (study day 33.0); relationship: POSSIBLE

mild assessed

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-06-23 (study day 33.0); relationship: POSSIBLE

mild assessed

Mild APPLICATION SITE URTICARIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-06-23 (study day 33.0); relationship: POSSIBLE

mild assessed

Mild CYST — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-05-13 (study day -9.0); relationship: NONE

mild assessed

Mild DEPRESSED MOOD — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-07-04 (study day 44.0); relationship: POSSIBLE

moderate assessed

Moderate DEPRESSED MOOD — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-07-04 (study day 44.0); relationship: POSSIBLE

mild assessed

Mild DYSPHONIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-11-03 (study day 166.0); relationship: REMOTE

mild assessed

Mild FATIGUE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-09-12 (study day 114.0); relationship: REMOTE

mild assessed

Mild ONYCHOMYCOSIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-05-13 (study day -9.0); relationship: NONE

Data queries

No data queries.